Arbutus Biopharma (ABUS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Arbutus Biopharma (ABUS) is Neutral.

The composite score behind that read is -0.03, weighing +0.11 of bullish evidence against -0.20 bearish.

Arbutus Biopharma last closed at $4.22, +0.96% on the session.

Against the IVW growth benchmark the position is +0.16% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

Arbutus Biopharma has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Arbutus Biopharma in the 96th percentile on valuation and the 95th percentile on return on equity, where 100 is best.

Arbutus Biopharma is classified under Health Care / Biotechnology, with a market capitalisation of $828.08M.

StockMap tracks Arbutus Biopharma as the 142nd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Arbutus Biopharma ranks 122nd of 381 in the group, against a group median of -0.08.